PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.72%
EBIT growth of 7.72% while Biotechnology median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
7.72%
Operating income growth of 7.72% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand.
12.50%
Net income growth of 12.50% while Biotechnology median is zero. Walter Schloss might see potential if moderate gains can keep rising.
15.94%
EPS growth of 15.94% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
15.94%
Diluted EPS growth of 15.94% while Biotechnology median is zero. Walter Schloss might see a slight edge that could improve over time.
4.10%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
4.10%
Diluted share growth above 2x Biotechnology median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-32.84%
Negative OCF growth while Biotechnology median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-32.79%
Negative FCF growth while Biotechnology median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-48098.63%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-29341.33%
Negative 5Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-23.11%
Negative 3Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-39968.68%
Negative 10Y net income/share CAGR vs. Biotechnology median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
-32.05%
Negative 5Y CAGR while Biotechnology median is 0.00%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-188.96%
Negative 3Y CAGR while Biotechnology median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
7755.72%
Equity/share CAGR of 7755.72% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
2687.68%
5Y equity/share CAGR of 2687.68% while Biotechnology median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
-9.18%
Negative 3Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.88%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-33.82%
Negative BV/share change while Biotechnology median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
No Data
No Data available this quarter, please select a different quarter.
-2.78%
R&D dropping while Biotechnology median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-14.34%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.